文献速递前列腺癌

ENACT试验前列腺肿瘤转录组分析:恩杂鲁胺联合主动监测的纵向变化

Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.
PubMed 文献 · BJU Int · 2025-07-31

基于ENACT试验(NCT02799745)中低/中危前列腺癌患者,对131例样本(恩杂鲁胺+主动监测57例,主动监测74例)在筛选期、第1年和第2年进行基因表达谱分析。第1年恩杂鲁胺+主动监测组出现雄激素受体信号和免疫抑制特征下调、免疫激活和基底样标志物上调,多数变化在第2年停药后恢复至基线。

要点

  • 恩杂鲁胺联合主动监测第1年可下调雄激素受体信号和免疫抑制特征。
  • 治疗期间免疫激活和基底样标志物上调,提示免疫调节机会。
  • 多数转录组变化在停药后第2年恢复至基线水平。

核心结论

  • 恩杂鲁胺联合主动监测可引起短暂的转录组改变,包括免疫调节,为探索免疫治疗策略提供线索。

研究设计与样本

  • ENACT试验(NCT02799745)的探索性生物标志物分析,纳入低或中危前列腺癌患者,共131例样本(恩杂鲁胺+主动监测57例,主动监测74例)。

主要发现

  • 第1年恩杂鲁胺+主动监测组出现雄激素受体信号和免疫抑制特征下调,免疫激活和基底样标志物上调。
  • 多数转录组改变包括免疫相关变化为短暂性,第2年停药后恢复至基线。

临床怎么用

  • 恩杂鲁胺短期暴露的免疫调节作用提示可探索与免疫治疗联合的策略。

局限性

  • 为探索性生物标志物分析,样本量有限,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low- or intermediate-risk prostate cancer, comparing the efficacy and safety of enzalutamide plus active surveillance (AS) to AS alone. PATIENTS AND METHODS: Gene-expression profiling was conducted using the Decipher Genomic Resource for Intelligent Discovery (GRID) platform (Veracyte, Inc.) on 131 patient samples (enzalutamide plus AS: n = 57; AS alone: n = 74) collected at screening, Year 1, and Year 2. Pre-defined GRID signatures were analysed for associations with biological and clinical features, including immune activity, treatment sensitivity, metastatic risk, and molecular subtypes. Statistical analyses utilised Cox proportional hazards models and logistic/linear regression, while longitudinal changes were evaluated using linear mixed-effects models. RESULTS: At Year 1, patients treated with enzalutamide plus AS showed significant transcriptomic changes, such as downregulation of androgen-receptor signalling and immune-suppressor signatures, alongside upregulation of immune-activated and basal-like markers. Many of these transcriptomic alterations, including immune-related changes, were transient and reverted to baseline levels at Year 2 after enzalutamide treatment cessation. CONCLUSION: This exploratory biomarker analysis highlights transcriptomic changes in patients undergoing AS and those treated with enzalutamide, providing insights into molecular disease progression on surveillance and the effects of transient exposure to enzalutamide. The observed immune modulation during enzalutamide treatment suggests opportunities to explore immunotherapy strategies.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Handa N, Shore ND, Cooperberg MR, et al. Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide. BJU Int. 2025. PMID: 40742002. doi:10.1111/bju.16861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。